Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Genetic predisposition and ovarian cancer].
Coupier I, Gauthier-Villars M, This P, Stoppa-Lyonnet D. Coupier I, et al. Among authors: this p. Rev Prat. 2004 Oct 31;54(16):1757-62. Rev Prat. 2004. PMID: 15630879 Review. French.
Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
Laki F, Kirova YM, This P, Plancher C, Asselain B, Sastre X, Stoppa-Lyonnet D, Salmon R; IC-BOCRSG IC-BOCRSG: Institut Curie - Breast Ovary Cancer Risk Study Group. Laki F, et al. Among authors: this p. Cancer. 2007 May 1;109(9):1784-90. doi: 10.1002/cncr.22603. Cancer. 2007. PMID: 17351952 Free article.
No peritoneal malignancy was observed. CONCLUSIONS: This study shows that prophylactic SO remains an important option for BRCA1/2 mutation carriers as asymptomatic ovarian/fallopian cancers were found in 4.5% of patients. However, a longer follow-up and larger series are r …
No peritoneal malignancy was observed. CONCLUSIONS: This study shows that prophylactic SO remains an important option for BRCA1/2 mut …
Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.
This P, de la Rochefordière A, Savignoni A, Falcou MC, Tardivon A, Thibault F, Alran S, Fourchotte V, Fitoussi A, Couturaud B, Dolbeault S, Salmon RJ, Sigal-Zafrani B, Asselain B, Stoppa-Lyonnet D; Institut Curie Breast and Ovarian Cancer Risk Study Group. This P, et al. Fam Cancer. 2012 Sep;11(3):473-82. doi: 10.1007/s10689-012-9539-1. Fam Cancer. 2012. PMID: 22711610 Clinical Trial.
Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
Kirova YM, Savignoni A, Sigal-Zafrani B, de La Rochefordiere A, Salmon RJ, This P, Asselain B, Stoppa-Lyonnet D, Fourquet A. Kirova YM, et al. Among authors: this p. Breast Cancer Res Treat. 2010 Feb;120(1):119-26. doi: 10.1007/s10549-009-0685-6. Epub 2009 Dec 24. Breast Cancer Res Treat. 2010. PMID: 20033769 Review.
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
Pujol P, Lasset C, Berthet P, Dugast C, Delaloge S, Fricker JP, Tennevet I, Chabbert-Buffet N, This P, Baudry K, Lemonnier J, Roca L, Mijonnet S, Gesta P, Chiesa J, Dreyfus H, Vennin P, Delnatte C, Bignon YJ, Lortholary A, Prieur F, Gladieff L, Lesur A, Clough KB, Nogues C, Martin AL; French Federation of Cancer Centres (FNCLCC). Pujol P, et al. Among authors: this p. Fam Cancer. 2012 Mar;11(1):77-84. doi: 10.1007/s10689-011-9484-4. Fam Cancer. 2012. PMID: 22076253 Clinical Trial.
[HRT in post menopausal women and breast cancer at the Institut Curie].
Czernichow C, This P, Asselain B, Falcou MC, Savignoni A, Salmon RJ; Groupe sein de l'Institut Curie; Sigal-Zafrani B. Czernichow C, et al. Among authors: this p. Bull Cancer. 2007 May;94(5):469-75. Bull Cancer. 2007. PMID: 17535785 Free article. French.
Surgical procedure, locoregional recurrence, metastasis, disease free and global survival were compared bet the patient who received an HRT versus the patients who didn't receive this treatment Mammographic diagnosis was more frequent in the HRT group and the age at diagno …
Surgical procedure, locoregional recurrence, metastasis, disease free and global survival were compared bet the patient who received an HRT …
[Standards, Options and Recommendations for the management of ductal carcinoma in situ of the breast (DCIS): update 2004].
Cutuli B, Fourquet A, Luporsi E, Arnould L, Caron Y, Cremoux Pd, Dilhuydy JM, Fondrinier E, Fourme E, Giard-Lefevre S, Blanc-Onfroy ML, Lemanski C, Mauriac L, Sigal-Zafrani B, Tardivon A, This P, Tunon de Lara C, Kirova Y, Fabre N; Federation of French Cancer Centres (FNCLCC), et le groupe de travail SOR. Cutuli B, et al. Among authors: this p. Bull Cancer. 2005 Feb;92(2):155-68. Bull Cancer. 2005. PMID: 15749645 Free article. French.
97 results